A Penicillin Allergy Delabeling Inhospital Model Hospitalized Patients (Des-Al-Pen)

Althaia Xarxa Assistencial Universitària de Manresa

Status: Terminated

Conditions: Allergy Drug; Allergy Penicillin

Treatments: Other: Pragmatic allergy management according to risk stratification

Study type: Interventional

Funder types: Other

Identifiers

NCT07194824

23/028

Details and patient eligibility

About

Design, implementation and analysis of an allergy assessment and management model beta-lactams in hospitalized patients

Full description

To evaluate the impact of a healthcare process for risk stratification based on the clinical history and the application of a structured questionnaire, on the Proportion of hospitalized patients in whom the penicillin allergy label is removed

Enrollment: 165 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Age > 18 years
• Ability to understand the study after reading the patient information sheet (Appendix II) and providing signed consent for participation (Appendix III: informed consent form).
• Patients with a reported allergy to penicillin and/or cephalosporins that has not been investigated or with inconclusive prior testing.

Exclusion Criteria

- None

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

165 participants in 1 patient group

Patients with an active allergy label for beta-lactams admitted to hospital

Experimental group

Description:

Clinical evaluation involving a review of the patient's history and a structured questionnaire, allows stratification of allergy risk into 3 categories, and managed accordingly. 1) Tipus A) Patients with a non-immune-mediated adverse reaction or with posterior tolerance. 2) Grup B) Patients with low risk potentiallly immune-mediated mechanism are considered candidates for exposure and re-exposure to penicillin and/or cephalosporins, as clinically indicted. 3\) Grup C) Patients with a previous adverse reaction considered high-risk Type C, IgE-mediated or non-immediate Type II-IV reactions,

Treatment:

Other: Pragmatic allergy management according to risk stratification